Answers are grounded in this paper and cite their sources.
Aim: The novel coronavirus disease 2019 (COVID-19) was first described in Wuhan, China, in December 2019. It has since spread worldwide, leading to high morbidity and mortality. Patients with chronic renal failure on dialysis who also have a confirmed diagnosis of active infection represent a risk group because infections are the second cause of death in this group, followed by immunosuppression caused by the weakening of the innate immunity by uremic toxins. This study aimed to describe the clinical characteristics of patients undergoing haemodialysis who also have a confirmed diagnosis for COVID-19 and its association with short-term outcomes.
No takes yet. Share an insight, caveat, or question.
Aroca et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: